Neurogene Inc.

NasdaqGM:NGNE Stock Report

Market Cap: US$266.9m

Neurogene Management

Management criteria checks 1/4

Neurogene's CEO is Rachel McMinn, appointed in Jan 2018, has a tenure of 8.08 years. total yearly compensation is $3.46M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 8.07% of the company’s shares, worth $21.54M. The average tenure of the management team and the board of directors is 2.2 years and 2.2 years respectively.

Key information

Rachel McMinn

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage17.17%
CEO tenure8.1yrs
CEO ownership8.1%
Management average tenure2.2yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation

Dec 31
Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation

Neurogene: From Speculation To Execution With NGN-401

Nov 24

We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth

Aug 13
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth

Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401

Mar 07

Neurogene: Interesting CNS Disease Company, Data Coming Soon

Nov 10

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Mar 26

CEO Compensation Analysis

How has Rachel McMinn's remuneration changed compared to Neurogene's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$85m

Jun 30 2025n/an/a

-US$84m

Mar 31 2025n/an/a

-US$81m

Dec 31 2024US$3mUS$595k

-US$75m

Sep 30 2024n/an/a

-US$3m

Jun 30 2024n/an/a

US$2m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$1mUS$468k

US$14m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$657kUS$448k

-US$55m

Compensation vs Market: Rachel's total compensation ($USD3.46M) is above average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.

CEO

Rachel McMinn (52 yo)

8.1yrs
Tenure
US$3,464,815
Compensation

Dr. Rachel L. McMinn, Ph D., is the Founder of Neurogene Inc. and Chief Executive Officer and Executive Chair of Board since December 2023. Dr. McMinn founded Private Neurogene in January 2018 and served a...

Leadership Team

NamePositionTenureCompensationOwnership
Rachel McMinn
Founder8.1yrsUS$3.46m8.07%
$ 21.5m
Christine Cvijic
President & CFO2.2yrsUS$3.36m0.33%
$ 880.0k
Julie Jordan
Chief Medical Officer2.1yrsUS$2.46m0.16%
$ 430.7k
Stuart Cobb
Chief Scientific Officer2.2yrsUS$784.32k0.088%
$ 234.2k
Donna Cochener-Metcalfe
Senior VP & General Counsel2yrsno data0.0013%
$ 3.4k
Andrew Mulberg
Senior Vice President of Regulatory Affairsno datano datano data
Ricardo Jimenez
Senior Vice President of Technical Operationsno datano datano data
Arvind Sreedharan
Senior Vice President of Business Operationsno datano datano data
2.2yrs
Average Tenure
52yo
Average Age

Experienced Management: NGNE's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rachel McMinn
Founder2.2yrsUS$3.46m8.07%
$ 21.5m
Robert Baffi
Independent Director2.2yrsUS$658.13k0.17%
$ 451.2k
Rohan Palekar
Independent Director3.9yrsUS$662.63k0.13%
$ 336.7k
Sarah Noonberg
Independent Director6.5yrsUS$650.13k0.13%
$ 355.7k
Cory Freedland
Independent Director2.2yrsUS$660.13k0.094%
$ 250.6k
Robert Woods
Independent Director2.2yrsUS$656.63k0.094%
$ 250.6k
2.2yrs
Average Tenure
57yo
Average Age

Experienced Board: NGNE's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/08 23:28
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurogene Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gum-Ming LoweCraig-Hallum Capital Group LLC
Mitchell KapoorH.C. Wainwright & Co.
Mani ForooharLeerink Partners LLC